Morning Market Movers

By: via Benzinga
Halozyme Therapeutics (NASDAQ: HALO) climbed 17.57% to $9.50 after the company reported that it will resume PEGPH20 clinical program in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.